Recombinant tissue Plasminogen Activator administration by retinal branch vein route for Central Retinal Vein Occlusion: a randomised conventional therapy controlled trial

INTERVENTION: Injection of rt‐PA (0.2 mg/ml, 4 ml) in retinal branch vein. CONDITION: Central Retinal Vein Occlusion (CRVO) ; Eye Diseases ; Central Retinal Vein Occlusion (CRVO) PRIMARY OUTCOME: BCVA on Early Treatment Diabetic Retinopathy Study (ETDRS) chart. SECONDARY OUTCOME: Reduction in:; 1. Neovascular changes; 2. Neovascular glaucoma ; 3. Rates of development of macular oedema INCLUSION CRITERIA: 1. Informed consent 2. Over 18 years of age 3. Adequate birth control (if not post‐menopausal or sterilised) during a two week pre‐ and six week post‐operative period if assigned to vitreoretinal surgery 4. Subjective decrease in visual acuity starting within four weeks prior to study start, due to CRVO, clinically evident by fundoscopy 5. Non‐perfused or perfused CRVO with a visual acuity of less than 20/200 Note : Pseudophakic patients are allowed to participate in this study.